Every 8-K that Accendra Health, Inc. (ACH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ACH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACH filings page.
Accendra Health, Inc. outlined updates to capital allocation and CEO succession. The company decided not to establish an at-the-market equity issuance program that had been contemplated to issue modest equity over time to reduce indebtedness, and stated this decision will have no impact on its results of operations or published guidance. Management reiterated confidence in liquidity, noting the company was undrawn on its $300 million revolving credit facility at the end of the second quarter and does not expect to rely on it other than for occasional working capital needs.
Accendra also reported opportunistic sales of two non-core assets, with one sale closed in the third quarter and the second expected to close before year-end, for a combined cash injection of approximately $45 million in the third and fourth quarters, with de minimis impact on Adjusted EBITDA. The board continues a long-standing CEO succession process and expects to announce a successor to CEO Dan Pesicka by mid-September 2026, ahead of his planned retirement by the end of 2026; he will remain CEO until a successor is in place and then serve in an advisory role.
Accendra Health, Inc. adopted a Section 382 Tax Asset Preservation Plan to help preserve its net operating loss carryforwards and other tax attributes by reducing the risk of an “ownership change” under the tax code. The board declared a dividend of one preferred share purchase right for each common share outstanding on August 20, 2026, issued under a Rights Agreement with Computershare Trust Company, N.A.
Each right allows the holder to buy one one-thousandth of a Series C Cumulative Preferred Share at a purchase price of $15.00, becoming exercisable if any person or group acquires 4.9% or more of the outstanding common stock, subject to detailed grandfathering and exemption provisions. If triggered, holders (other than the acquirer) can acquire common shares at a value equal to two times the exercise price, or the company may exchange each right for one common share. The plan can be redeemed by the board for $0.001 per right and is scheduled to expire at the close of business on August 10, 2029. In connection with the plan, the board approved Articles of Amendment designating the Series C Cumulative Preferred Stock.
Accendra Health reported second quarter 2026 results for its continuing operations, highlighting both ongoing losses and significant balance sheet changes. Net revenue was $613.2 million, down from $681.9 million a year earlier, with a GAAP loss from continuing operations of $89.1 million versus $83.8 million. Adjusted net loss was $14.3 million compared with adjusted income of $20.5 million, and Adjusted EBITDA declined to $60.1 million from $96.6 million. Free cash flow swung to negative $25.1 million from positive $15.2 million, while cash and cash equivalents fell to $7.7 million at June 30, 2026.
The company completed a balance sheet optimization, reducing outstanding debt by $385 million in the quarter and extending its weighted average debt maturity from about 2.7 to 5.5 years, leaving net debt at $1.71 billion. For full-year 2026, Accendra reaffirmed and updated guidance to revenue of $2.45–$2.55 billion, Adjusted EBITDA of $300–$320 million, and free cash flow around breakeven to slightly positive. The company also disclosed that President & CEO Edward A. Pesicka intends to retire by the end of 2026, with a succession process underway.
Accendra Health, Inc. announced that President, Chief Executive Officer and Director Edward A. Pesicka plans to retire and step down from the Board by the end of 2026, or earlier if a successor is appointed. The company states that his decision is not due to any disagreement regarding operations, policies or practices.
The Board has an established succession planning process and has previously identified potential candidates, and will now evaluate and select the next President and CEO. Mr. Pesicka may serve in an advisory capacity beyond his retirement to support a smooth transition. Accendra also highlighted a previously announced investor conference call for second quarter 2026 results on August 10, 2026 at 8:00 a.m. E.T., accessible via webcast and dial-in numbers.
Accendra Health, Inc. reports the expiration and final results of its exchange offers for its 4.500% Senior Notes due 2029 and 6.625% Senior Notes due 2030. Eligible holders tendered approximately $478.3 million of 2029 Notes and $548.0 million of 2030 Notes, representing about 99.9% and 99.2% of the amounts outstanding at launch. After cancellation of exchanged notes, $338,000 of 2029 Notes and $4,170,000 of 2030 Notes remained outstanding. In connection with the exchanges and a new money issuance, the company issued $213.0 million of First Lien Notes and $698.1 million of Second Lien Notes for existing notes, plus $326.25 million of new money First Lien Notes, for a total of $539.25 million First Lien Notes.
Accendra Health, Inc. is executing a major liability management transaction, exchanging nearly all of its unsecured senior notes for new, higher-coupon secured notes and putting new credit facilities in place. As of the early exchange deadline, holders tendered approximately $478.3 million of 4.500% notes due 2029 (about 99.9% outstanding) and $547.9 million of 6.625% notes due 2030 (about 99.2% outstanding). The company accepted and cancelled these notes and issued $213.0 million of 9.000% First Lien Notes due 2032 and $698.0 million of 9.750% Second Lien Notes due 2033, plus $326.25 million of new-money First Lien Notes, for a total of $539.25 million First Lien Notes. Only $363,000 of 2029 notes and $4.257 million of 2030 notes remain outstanding. Accendra also replaced its existing revolver with a new $300.0 million revolving credit facility due 2030 and amended its term loan to waive mandatory prepayments on $400.0 million of asset sale proceeds and to permit the new secured notes and related liens, all subject to leverage and interest coverage covenants.
Accendra Health, Inc. has launched exchange offers and related consent solicitations for its outstanding 4.500% Senior Notes due 2029 and 6.625% Senior Notes due 2030. Eligible holders can swap these unsecured notes into newly issued 9.000% senior secured first lien notes due 2032 and 9.750% senior secured second lien notes due 2033, with different consideration levels depending on participation in a new money notes issuance and early tender deadlines. The company is also raising $326.25 million in new first lien notes for cash and seeking consents to strip most covenants and certain events of default from the existing indentures. Accendra notes the offers are subject to multiple conditions and warns that failing to complete these or alternative transactions on favorable terms could materially adversely affect its financial condition.
Accendra Health, Inc. reported results from its 2026 Annual Meeting of Shareholders. Shareholders approved the Accendra Health, Inc. Amended and Restated 2023 Omnibus Incentive Plan, which replaces the prior 2023 plan and allows the Board’s Our People & Culture Committee to grant equity and other incentive awards to employees, non-employee directors and consultants.
At the meeting, 76,437,917 shares were entitled to vote and 62,134,133 shares were voted, representing approximately 81.29% participation. Six director nominees each received over 48.7 million votes for, including 51,189,677 votes for Teresa L. Kline, with detailed vote counts and broker non-votes reported for all proposals.
Accendra Health is pursuing a comprehensive balance sheet overhaul built around new secured debt, note exchanges and amended bank facilities. The company agreed to offer $326.25 million of new 9.000% Senior Secured First Lien Notes due 2032, alongside exchange offers and consent solicitations for its existing 4.500% 2029 and 6.625% 2030 senior notes.
Certain noteholders and term loan lenders have committed, subject to conditions, to backstop $261.0 million of the new first lien notes and up to an additional $65.25 million, and to tender all of their existing notes in the exchanges. Revolving lenders have committed to a new $300.0 million revolving credit facility due 2030, and term lenders have agreed to consents and covenant changes, including waiving mandatory prepayments tied to $400.0 million of asset sale proceeds.
The company’s confidential investor deck highlights its post-divestiture profile as a pure‑play home‑based care platform with about $2.8 billion of FY2025 revenue, diversified chronic‑care exposure, and management’s projections for mid‑teens adjusted EBITDA margins, strong free‑cash‑flow generation and lower leverage after the transaction.
Accendra Health reported a first-quarter 2026 net loss from continuing operations of $6.5 million, or $0.08 per share, on net revenue of $627.8 million, down from $673.9 million a year earlier. Operating income was $17.1 million, but higher interest expense contributed to the loss.
Non-GAAP results weakened, with adjusted net loss of $3.1 million versus adjusted net income of $23.2 million and adjusted EBITDA of $58.4 million versus $96.0 million. Free cash flow turned slightly negative at $(2.0) million. Cash rose to $336.9 million, while net debt remained high at $1.77 billion.
The company also announced commitments from existing creditors for a more than $1.5 billion comprehensive balance sheet optimization transaction intended to extend debt maturities, reduce total leverage and reset its capital structure as it continues its shift to a pure play home-based care business.
Accendra Health, Inc. reported fourth-quarter and full-year 2025 results that reflect its shift to a standalone home-based care business after completing the sale of its Products & Healthcare Services business on December 31, 2025.
From continuing operations, net revenue rose to $708.967 million in Q4 2025 from $695.023 million a year earlier, with Q4 operating income improving to $20.9 million from a loss of $272.7 million. For 2025, continuing net revenue grew to $2.762 billion from $2.680 billion, and adjusted EBITDA was $374.847 million versus $370.515 million in 2024.
Despite better underlying performance, the company recorded a substantial full-year net loss of $1.1006 billion, driven largely by a $997.960 million loss from discontinued operations and an $80 million transaction breakage fee related to a terminated acquisition. Cash and cash equivalents increased markedly to $281.989 million at December 31, 2025, and net debt declined to $1.768 billion, while total equity moved to a deficit position. Management highlighted strong cash flow, ongoing cost controls and balance sheet optimization as it completes separation from Owens & Minor and focuses on sustainable growth.